Pressure BioSciences, Inc. (PBIO)

[QualityStocks]

Pressure BioSciences (PBIO) is focused on developing products based on its proprietary pressure cycling technology (PCT) for life-sciences applications. The innovative technology utilizes hydrostatic pressure, which cycles between ambient and ultra-high levels, to rapidly and proficiently disrupt cell membranes/tissues to remove nucleic acids, proteins, and small molecules from plant and animal materials.

The PCT technology has a broad range of possible applications in genomics and proteomics, in addition to drug discovery, pathogen inactivation, food safety, immunodiagnostics, and DNA sequencing. Currently, the PCT System consists of a top-of-the-line instrument and disposable PULSE sample processing tubes. Pressure BioSciences plans to develop other instrumentation and disposables to meet additional needs in life sciences’ laboratories.

The Company’s proprietary technology addresses the number one issue in sample preparation that creates significant bottlenecks in research. Existing technology does not product consistent results, requires multiple steps, and has a high risk of contamination. By utilizing Pressure BioSciences’ PCT technology, researching can achieve much better results in a single-step process.

The CEO and President of Pressure BioSciences, Mr. Richard T. Schumacher, founded the company in 1978 as Boston Biomedica, which later became known as Pressure BioSciences in 2004. He has extensive experience in the medical field, helped build Panacos Pharmaceuticals into a public company valued at more than $200 million, and guided Boston Biomedica from a start-up company to realizing $30 million in sales as Pressure BioSciences.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) - Pressure First, Profits Next

As technology advances leaps and bounds, one thing becomes blazingly clear; the general public, including the average investor, is often unable to fully understand just what the technology “does”. This isn’t just an isolated incident comprised of a group of below average intelligence consumer/investors, but instead is a widespread problem, confounding even the very analysts that are researching the companies.

Nowhere is this situation more evident than in the medical technology field. The advances in genomics, proteomics, drug discovery & development, process purification, pathogen inactivation, immunodiagnostics, DNA sequencing, and all facets of microbiology have been fantastic to say the very least. Yet as with most esoteric and extremely high tech developments, often it’s just a very small body of people with very specialized knowledge of the application that can fully understand and grasp the enormity of what’s being presented. For the layman however, the old adage of “like explaining the theory of relativity to a cave man” comes to mind. Without the years of specialized education, how is it possible to fully understand the capabilities and opportunities present in a new development? Often it’s simply not possible without some hand holding and guidance.

Pressure Biosciences is a company that exemplifies this very situation. Publicly traded under the ticker PBIO, this medical device company has a very very exciting machine it has developed to do very specialized sampling. Yet to the layman, or even a relatively advanced medical device analyst, the Jargon can seem daunting if not completely foreign. Let’s take a sample from their own web page as an example: “Specifically, lysis occurs when samples are subjected to alternating cycles of ambient and high pressure, up to 35,000 psi, in the hydrostatic reaction chamber” or “Our data also suggest that proteins and lipids can be isolated as two distinct fractions in a single step, thus allowing for the independent analysis of these molecules from a single sample in a far more rapid and efficient manner than possible with current methods. Finally, based on our results, we believe that lipids and proteins obtained using the PCT-dependent method will not require any additional purification to be directly compatible with HPLC, LC/MS analysis, and gel electrophoresis.”

We are quite certain that if you asked a random cross section of the population what that all means, or better yet, what sort of opportunity it creates, the image of a “blank stare” comes to mind. This is simply technology far and above the general knowledge level and thus can become something akin to “noise” to the investing public. This is why we find that tremendous opportunities are often passed by, simply because no one “got it”.

In simpler terms Pressure Biosciences has fashioned a way to subject cells to a wave of high and low pressure extremes that “busts” a cells membranes and thus it releases its contained proteins. This may not sound earth shattering at first light, but consider this. Before their “BaroCycler” was developed, virtually every other method of collecting pure cellular proteins of the study subject, were deficient in some way. Whether it was temperature differences, time of extraction differences, detergent tracers masking results, or any number of other variables, the fact is that you cannot do cutting edge research and discovery if your sample isn’t pure.

Once you have a pure sample and the variables of the testing have been removed, then it’s a much more exact science to try and locate the specific differences, markers, and characteristics that various proteins exhibit when disease is present. In fact, when their “Barocycler” machine was used in conjuncture with their newest patent pending method of combining their Pressure cycling technology with certain organic solvents, it has been proven to expose even more proteins from a single cell than ever realized before. Is this important and exciting? Indeed it is, and as witness to its value, some 20+ of the world’s most prestigious medical research facilities are now utilizing PBIO’s technology. As more proteins are discovered and collected, researchers have more chances to better understand their properties. Ultimately, therapies and cures can indeed hinge on proper specimens to work upon.

As medicine delves further into the world of the miniature in their fight against cancers, virus’s, genetic disorders, obesity and the gambit of modern ills, technology such as Pressure Biosciences will take center stage in their arsenal of tools to unlock the codes, and find the cures. As technology advances, the specimens provided by PBIO’s technology could very well be used in the next “breakthrough”. Now that’s a term all of us can understand.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure Biosciences, Inc. (PBIO) Places Focus on Battling Obesity with Patented Technology

According to the U.S. Centers for Disease Control and Prevention’s (CDC) most recent statistics, obesity is the number one health threat facing Americans, killing about 400,000 people each year with medical and other costs tipping the scale near $123 billion annually. Pressure Biosciences, Inc.’s (Nasdaq: PBIO) patented technology may come in useful in fighting America’s rising killer.

Pressure Biosciences’ pressure cycling technology (PCT) uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The technology has applications in genomics (the study of an organism’s hereditary information encoded in its DNA), proteomics (study of structures and functions of proteins) and nucleic acid testing with the ability to rupture cells to release significantly more proteins in fatty tissues.

As the battle of the bulge continues, Pressure Biosciences has expanded its product line, boosted its sales force, stacked up “ample” inventory and a has full service spectrum. The company intends on focusing on laboratories conducting obesity research using PCT because of its ability to extract proteins from lipid-rich tissue samples.

According to a Taglich Brothers report, the worldwide market for PCT, and other technologies developed by Pressure Biosciences, consists of 45,000 laboratories in various institutions. As demand for the development and production of more efficient drugs rises, so has the interest in proteomics.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences Inc. (PBIO) to be Featured at the RedChip Small-Cap Investor Conference

RedChip announced this morning that the CEOs and executive teams of 30 emerging small-cap companies will be presenting at this year’s RedChip Small-Cap Investor Conference at the Four Seasons Resort in Scottsdale, Arizona - Feb. 7, 2008, from 8 a.m. to 5 p.m.

The conference is known around the nation for featuring small-cap companies who have remarkable stories to present in front of hundreds of investment bankers, fund managers, institutional and accredited investors, research analysts, and high net worth individuals.

Presenters such as Pressure BioSciences will also have the opportunity to meet with RedChip’s top retail brokers, institutional brokers, and financial advisors. The event will include expo-style exhibitions, networking events, and financial presentations by other small-cap companies representing an array of sectors including biotechnology, alternative energy, oil & gas, consumer services, business services, manufacturing, laser technology, Internet software & services, and more.

The conference will include presentations from GeoPharma Inc. (Nasdaq:GORX), Worldwide Manufacturing USA Inc. (OTCBB:WWMU), Pressure BioSciences Inc. (Nasdaq:PBIO), ZAGG Inc. (OTCBB:ZAGG), Alternative Construction Technologies Inc. (OTCBB:ACCY), Carbon Sciences Inc. (OTCBB:CABN), Duska Therapeutics Inc. (OTCBB:DSKA), Newtek Business Services Inc. (Nasdaq:NEWT), QPC Lasers Inc. (OTCBB:QPCI), Sharps Compliance Corp. (OTCBB:SCOM), PetroSouth Energy Corp. (OTCBB:PSEG), Onstream Media Corp. (Nasdaq:ONSM) and more than 15 other emerging growth companies.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) Prices Surge over 18% on Skyrocketing Volume

After Redchip’s announcement this morning that Pressure BioSciences would be a featured company in their upcoming investor conference, prices surged to reach a High-of-Day at $6.82, which is 18.2% higher than yesterday’s close. Volume also exploded reaching a 852% increase compared to the 15 day average.

Dutton Associates recently issued a research note reiterating their “Strong Speculative Buy” rating and initiating price target of $10. In conclusion of the independent report, the analyst stated, “In sum, we believe that Pressure BioSciences has attained its short-term goals regarding commercialization and is well poised to continue to market its PCT systems in the U.S. along with its plan to expand overseas by collaborating with appropriate research laboratories. We reiterate our Strong Speculative Buy rating with a 12-month target of $10.00.”

The company announced last month that total revenues increased from $92,211 in the third quarter of 2006 to $138,052 for the same quarter of this year. The primary cause of the increase can be attributed to the increased number of installations of the Company’s Pressure Cycling Technology (PCT) Sample Preparation Systems. The innovative systems can be used in an array of possible applications including genomics and proteomics, in addition to drug discovery, pathogen inactivation, food safety, immunodiagnostics, and DNA sequencing.

A video demonstrating the technology can be found at the following link: http://www.pressurebiosciences.com/videos/video.html

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure Biosciences, Inc. (PBIO) Disease-Fighting Technology Earns Award and Applause

Pressure Biosciences, Inc. (NASDAQ: PBIO), a life sciences company based in Massachusetts, researches, develops, and commercializes on sample preparation systems. The company’s cornerstone is its pressure cycling technology (PCT) that has the ability to use hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. In layman’s terms, the company’s technology opens the door to further insight into diseases such as obesity, heart disease, diabetes and certain cancers.

The company’s efforts are not only contributing to technological advancement, but are also winning awards. Last month, Pressure Biosciences was awarded the 2007 North American Frost & Sullivan Award for Technology Innovation. The award was given for Pressure Biosciences’ PCT paired with its ProteoSolve-LRS kit.

“Unlike conventional methods of tissue delipidation that comprise several stages such as cell and tissue disruption, protein extraction from lipids, and partitioning, the new PCT-dependent sample preparation approach from Pressure BioSciences combines these complex stages into a single step, as a result of which the fractions of proteins and lipids generated from each sample can be analyzed individually, faster, more efficiently, and with more reproducibility,” Sandhya Kamath, senior research analyst for Frost & Sullivan stated in a recent press release. “Moreover, this approach integrates PCT and reagents to extract and fractionate proteins from lipid-rich tissues in a detergent-free manner.”

While the lingo and technology of the PCT process might be a foreign language to most of us, the diseases that Pressure Biosciences focuses on hits close to home to many Americans. Obesity, heart disease and diabetes are among the nation’s top killers, and Pressure Biosciences has positioned itself to shed light on further research to stop them.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure Biosciences, Inc. (PBIO) Reports Increase of Sales, Revenue, and Cash on Hand

Pressure Biosciences, Inc. (NASDAQ: PBIO) recently reported the sale of four of its Barocycler NEP3229 PCT Sample Preparation Systems. Compare that to the sale of only one system in the second quarter of last year, and you’ve got a company on the move.

The company also posted $65,772 in grant revenue for the quarter ended June 30, 2007; last year it reported none. Additionally, Pressure Biosciences posted $202,127 for the second quarter of 2007, as compared to $28,783 in the same period of 2006. Cash on hand as of June 30, 2007, was about $6.8 million, up from $5.3 million reported as of December 31, 2006.

Increases across the board are attributed to an increase in sales of certain equipment, including the Barocycler and (Pressure Used to Lyse Samples for Extraction) PULSE-Tubes, as well as the sale of the company’s remaining shares held in Panacos Pharmaceuticals and the remaining divestiture of Source Scientific, LLC.

The technology behind the numbers is the pressure cycle technology (PCT), which is used in many life-science applications. The technology allows for a better understanding of circumstances leading to strokes, the detection of colon cancer, and the detection of proteins with embryo viability.

PCT uses hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The company’s product line includes the Barocycler and PULSE Tubes, which comprise the PCT system. Pressure Biosciences holds 13 U.S. patents, and five foreign patents spanning broad applications in life sciences including protein purification, proteomic, DNA sequencing and food safety.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) Recently Awarded $7 Price Target

RedChip analyst, Joe Blanksenship, MBA, awarded Pressure BioSciences a $7.00 price target and rated their stock a “Speculative Buy” following the company’s Q2 2007 report. In the research report, the analyst stated, “Pressure Biosciences, Inc. continues on its path to commercialization with its pressure cycling technology (“PCT”) used in sample preparation across a broad range of life-sciences applications.”

The Company reported the sale of four Barocycler NEP3229 PCT Sample Preparation Systems compared to the one sold in the same period last year. $202,127 was announced as the total revenue for the quarter, which is approximately 7x the amount from Q2 2006. $65,772 was recorded as grant revenue, while no grant revenue was recorded in the same quarter last year.

Pressure BioSciences’ balance sheet also improved as the company reported $6.8 million in cash and equivalents, a significant rise from the $5.3 million reported December of 2006. The sale of remaining stock held in Panacos Pharmaceuticals and the remaining divestiture of Source Scientific, LLC resulted in the receipt of about $3.0 million in cash.

In the conclusion of their report Joe Blanksenship, MBA stated, “The Red Chip Initial Report on PBIO was issued on March 12, 2007 with a SPECULATIVE BUY rating and 12-month price target of $6.40 per share. We continue to think that the current market price of the stock at $4.11, and a book value of $3.77 per share, does not adequately value the technology within the company. As the number of unit sales continues to grow and the potential applications expand, we believe that the market will begin to recognize the profit potential inherent in this Company. We are maintaining our twelve-month price target at $7.00 per share”

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure Biosciences, Inc. (PBIO) Develops Barocycler NEP2320 with Advanced Features

Pressure Biosciences, Inc. (NASDAQ: PBIO) focuses on the development of a technology called Pressure Cycling Technology (PCT) which, by definition, uses rapid cycles of hydrostatic pressure between ambient and ultra high levels to control biomolecular interactions, allowing for a high degree of precision, reproducibility, convenience, speed and safety. One application for the technology is to aid researchers in understanding obesity and other diseases.

The Barocycler NEP2320 is one such PCT device designed for laboratories that want improved sample preparation in genomics, proteomics, transcriptomics and metabolomics. Processing one sample at a time, the Barocycler NEP2320 uses laboratory compressed air, bottled compressed air, or a stand-alone compressor to create high levels of hydrostatic pressure inside its reaction chamber. The Barocycler NEP2320 is smaller than the NEP3229, but still allows the user many features, including temperature control.

Pressure Biosciences designed the machine to fit in smaller spaces, taking up less space on a laboratory bench, but still providing the same power desired in PCT, using the same Pressure Used to Lyse Samples for Extraction (PULSE) Tubes as the NEP 3229. PULSE Tubes function as transmitters, sending the “Power of PCT” from Barocycler to the sample.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences Inc. (PBIO) is “On Alert”

Pressure BioSciences Inc. is a life sciences company we have followed for much of this year through our relationship with the Red Chip Conferences. Pressure BioSciences, Inc. shares were hit with an inexplicable sell off this week, which has many speculating the sell off could be due impart to investor confusion linking Pressure BioSciences, Inc. and Panacos Pharmaceuticals Inc. which neared its 52 week low after disappointing results from Panacos HIV drug candidate bevirimat. Pressure BioSciences Inc. did initially have a passive investment in Panacos Pharmaceuticals, but sold off all of its interest in the investment over six month ago, as an opportunity to strengthen its cash position. The unexpected drop in price may give investors a chance to jump on (PBIO) shares at a reduced price.

Pressure BioSciences Inc. continues to make advancements regarding its pressure cycling technology (PCT). Frost & Sullivan announced that Pressure BioSciences, Inc. has been named the recipient of the 2007 North American Frost & Sullivan Award for Technology Innovation. The award is in recognition of the development and advancements regarding the combination of the Company’s Pressure Cycling Technology (PCT) with the innovative chemistry of its ProteoSolve-LRS kit. The breakthrough is significant because it streamlines and improves upon the complex process of development of a method for the detergent-free extraction of proteins from lipid rich tissues, resulting in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling.

Frost & Sullivan Senior Research Analyst Sandhya Kamath stated in the report “Protein expression from lipid rich tissues is crucial to understanding many disease states such as obesity, heart disease, diabetes, and certain cancer types, among others.” “As a result, sample preparation is drawing attention in proteomic studies since it can affect the accuracy and the overall quality of the downstream analytical processes.”

Pressure BioSciences Inc. recently presented its study which is focused on the discovery and identification of potential bio markers of colon cancer that used pressure cycling technology (PCT) for the extraction of proteins from colon cancer tissues bio markers. The purpose of this study was to identify proteins in tissue samples from patients with colon cancer that might be reliable bio markers for this disease. In the past identifying patients with this disease who have been shown to benefit from therapy is difficult due to the lack of reliable bio markers.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) ProteoSolve-LRS Technology Plays Significant Role in Identyfing Potential Biomarkers in Cancer

Pressure BioSciences announced this morning that the scientists at New York University reported that the Company’s award winning technology, the ProteoSolve-LRS, had a large part in identifying potential biomarkers in breast and colon cancer tissue. The results were presented at the LC-MS Course and Symposium, Robinson College, Cambridge, England by Dr. Paul Pevsner of the NYU School of Medicine Department of Pharmacology.

The ProteoSolve-LRS was recently released by the company to provide a solution for the detergent-free removal of proteins from lipid-rich tissues as well as other tissues. The study of proteins could lead to a better understanding of many disease states such as cancer. To be effectively studied, protiens have to be extracted from the cells and tissues they reside in.

Currently, there are multiple technical issues that hinder the removal of proteins, especially those rich in lipids. These challenges could be hindering great discoveries that might lead to new therapeutics and diagnostics. Pressure BioSciences believes that its ProteoSolve-LRS method, combined with its pressure cycling technology, will open the door for proteomics researchers to achieve more rapid, more reproducible, and higher quality protein extraction results when compared to other conventional methods.

The principle investigator for the research studies, Dr. Paul H. Pevsner, stated, “Our studies showed that the combination of cycled high pressure (PCT) with the ProteoSolve-LRS kit, used in conjunction with other instrumentation in our laboratory, allowed us to identify potential biomarkers of breast and colon cancer. This is a significant finding, since these potential biomarkers may prove to be important indicators of disease detection and progression. It is possible that these findings may alter the current paradigm of histopathology tissue diagnosis for tumors. In the future, examination of biopsy tissue may require not only histopathology, but also mass spectrometry for complete diagnosis.”

He continued to add, “The combination of PCT and ProteoSolve-LRS is particularly suited for the study of the small, often nano-quantities of samples that are usually available for proteomic studies. The combination of this method with mass spectrometry instrumentation may become a method of choice for bio-molecular identification, not just in cancer, but in neurological and coronary diseases as well.”

Previously announced last month, Frost and Sullivan gave Pressure BioSciences the “2007 North American Frost and Sullivan Award for Technology Innovation.” The Award recognized PBI for “the development of a method for the detergent-free extraction of proteins from lipid-rich tissues. This novel approach combines the power of the Company’s pressure cycling technology (PCT) with the innovative chemistry of its ProteoSolve-LRS kit, resulting in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling.”

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Dutton Associates Maintains “Speculative Buy” Rating and $10.00 Price Target for Pressure BioSciences Inc. (PBIO)

Dutton Associates announced today that it has updated its coverage of Pressure BioSciences and that it is reiterating its “Speculative Buy” Rating and $10.00 Price Target. Dutton’s Senior Analyst, Mr. Denise T. Resnik, M.S., completed the 17-page report.

The research firm stated in the press release, “We are reiterating our rating of Pressure BioSciences Inc. as a Strong Speculative Buy and our 12-month price target of $10.00 per share. The Company has developed a unique and superior technology for the preparation of biological laboratory samples and is in the early stages of commercialization of its product platform. We expect that the shares will begin to reflect the substantial profits that we believe the Company can generate beginning in 2010.”

Dutton Associates continued to say, “We believe that as the coming 12-month period progresses, Pressure BioSciences will begin to demonstrate its ability to place a rapidly-increasing number of Barocyclers, and that the potential for substantial profits beginning in 2010 will begin to be recognized in these shares. Accordingly, we have established a 12-month price target of $10. Based on a 20 multiple of projected 2010 earnings per share of $1.51, a substantially higher 12-month target stock price could be generated even if this future value is discounted at a rate that reflects the risks to our projections.”

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) Products Aid in the Study of Diabetes, Cancer, ALS, Heart Disease and Other Disorders

Barocycler NEP3229: The Barocycler NEP3229 is a high-pressure laboratory instrument that is designed to fit on a bench top, inside a biological safety cabinet, or on the shelf of a cold room while having the power to generate up to 35,000 psi. The instrument has the ability to process up to three samples at the same time by utilizing specially designed PULSE Tubes. An external chiller hook-up, automatic fill and dispense valves, and an integrated microprocessor with programmable logic controller is included.

Barocycler NEP2320: The Barocycler NEP2320 is a more compact alternative of the Barocycler NEP3229. It has the same technology advantages as the larger instrument, but processes one sample at a time and is designed to use a small amount of laboratory bench space. The Barocycler NEP2320 is controlled by specialized components, a programmable controller, and software. External sources such as compressed air, bottled compressed air, and stand-alone compressors are used to create high and ultra-high hydrostatic pressure inside the instrument’s reaction chamber.

PULSE Tubes: PULSE is an acronym for “Pressure Used to Lyse Samples for Extraction.” The tubes are used with both Barocycler products and transmit the pressure generated by the instruments to the sample. Specimens are placed on the lysis disk contained in the PULSE Tube and the tube is placed in the pressure chamber where pressurization begins. When pressure is released, the specimen is pulled back through the lysis disk. The combination of passing through the lysis disk, rapid pressure changes, and other biophysical mechanisms breaks up cellular structures swiftly and resourcefully, releasing the nucleic acids, small molecules, and proteins.

ProteoSolveLRS: Towards the mid-point of this year, Pressure BioSciences began marketing its first pressure-cycling dependent, research-use only kit named ProteoSolveLRS, which is currently patent pending. The special kit is made to safely, rapidly, resourcefully, and reproducibly extract proteins from lipid-rich samples. The Proteomic analysis of such samples is widely used to study diabetes, cancer, ALS, heart disease, and a plethora of other disorders related to obesity. The kit includes specific buffers, solvents, PULSE Tubes and instructions for use with purchased or leased Barocycler instruments.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) Making Substantial Progress Following Strategic Business Plan

Pressure BioSciences has been committed to accomplishing its corporate goals for this year and has experienced success in many areas. The Company brought seven full-time sales directors on board to achieve better regional coverage, which exceeds the initial goal of five. The new sales team has previous experience selling either sample preparation or life sciences capital equipment and many have worked in laboratories. The Company is currently training the new hires and anticipates the team to be fully operational early next year.

The company has also succeeded in increasing sales as a total of 10 Barocycler NEP3229 were commissioned. Four of the ten were commissioned within the third quarter, two of which were sold while the other two were leased or rented. The company’s lightweight model also sold well as four of them have been installed within the third quarter of this year. An additional 40 units have been ordered from Pressure BioSciences’ manufacturer.

Pressure BioSciences also launched its first PCT-dependent research-use only kit which is designed to extract proteins from lipid-rich samples. In conjunction with solvents and Pressure Cycling Technology, this extremely useful tool can benefit thousands of scientists worldwide working in the areas of obesity and other related diseases. The kit is unique as it can extract proteins from lipid-rich samples without using potentially harmful detergents.

In an effort to expand its foreign distribution and commercialize PCT globally next year, the Company applied for CE Marks on both of its innovative instruments. As of the second week of September, Pressure BioSciences was awarded approval for both devices. The Company is actively identifying scientists outside of the US and anticipates that these scientists are beginning to generate data to prepare for commercialization in Q1 2008.

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) is Making the Right Steps as Scientists and Research Firms Around the Nation Take Notice

Pressure BioSciences has continued to add research and development personnel to its staff to expand the number, as well as the scope, of R&D projects underway. The Company anticipates that its increased investments in R&D will complement its commercialization efforts by encouraging the continued publication of application notes in areas currently using PCT technology and creating new inventions that rely on its PCT technology.

The Company recently announced that a study focused on the discovery and identification of potential biomarkers of colon cancer was presented at the Annual Scientific Meeting of the American College of Gastroenterology (ACG). The study specifically used PCT technology for the extraction of proteins from colon cancer tissue. The results generated show that a tumor signature protein extracted from colon tumor tissue might be a biomarker for colon cancer. Patients could be treated earlier in the disease if reliable biomarkers can be identified for colon cancer.

Nearly a month later scientists at the New York University School of Medicine announced that the use of Pressure BioSciences’ ProteoSolveLRS method combined with PCT was actively involved in identifying potential biomarkers in breast and colon cancer tissue. The reported results were presented during the recent LC-MS Course and Symposium, Robinson College, Cambridge, England by Dr. Paul Pevsner of the NYU School of Medicine, Department of Pharmacology.

Furthermore, the Company was named the recipient of the prestigious 2007 North American Frost and Sullivan Award for Technology Innovation. The award was given to Pressure BioSciences because its technology can extract proteins from lipid-rich tissues without the use of detergents. This cutting-edge method results in higher protein recovery, enhanced reproducibility, and significant advantages in speed and handling.

As stated by Dutton Associates in a recent research report, which included a $10.00 Price target, “Internal and external research into additional uses of Pressure Cycling Technology further validates Pressure BioSciences’ approach to sample preparation and adds to the attractiveness of the technology and the Company.”

"Please see the disclaimers on the QualityStocks.net website."

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) has Finances In Order and Anticipating a Successful 2008

Pressure BioSciences ended the third quarter of this year with $6.0 million in cash. The use of cash by operations matched up with expectations that the company’s cash position could finance operations into the last part of 2008.

In March, the company sent a purchase order to Source Scientific, LLC to purchase 20 Barocycler NEP3229 units and 9 Barocycler NEP2320 units. The finished products will remain at Source Scientific until needed, then be shipped directly to Pressure BioSciences’ customers. The company anticipates that all of these units will be completely fabricated and available for sale early next year.

Because Pressure BioSciences already took possession of all 9 of the Barocycler NEP2320 units, another purchase order was sent to purchase an additional 40 Barocycler NEP2320 units. This second order is expected to be completed by the end of 2007 or early 2008.

Pressure BioSciences intends to continue increasing its level of activity in all areas for the rest of 2007 and into the New Year. The Company’s also plans to increase spending on selling and marketing activities, which will further raise awareness of their technology within the scientific community.

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) Shares Rebound Over 7%

After an inexplicable sell off, PBIO shares rebounded strong. The falling share price has been attributed by many to have been caused by confusion linking Pressure BioSciences, Inc. and Panacos Pharmaceuticals Inc. which neared its 52 week low after disappointing results. Previously Pressure BioSciences had a position in Panacos Pharmaceuticals, but sold off all its interest over six months ago.

The Company has attracted the attention of several analysts and has been awarded 12-month price targets as high as $10 – a near double from the current price. The most recent report published by Dutton Associates on December 18 detailed that shares will begin reflecting the substantial profits that are believed to be generated in 2010.

The projected sales of the Company’s flagship Barocylcer products are estimated to be a total of 24 for 2007, 218 for 2008, 568 for 2009, 1,108 for 2010, and over 1900 for 2011. Dutton Associates estimated that 2010 earnings will total $5.28 million resulting in Earnings Per Share of approximately $1.51 on a 3.49 million fully diluted share base.

In conclusion of their report, the firm stated, “We believe that as the coming 12-month period progresses, Pressure BioSciences will begin to demonstrate its ability to place a rapidly-increasing number of Barocyclers, and that the potential for substantial profits beginning in 2010 will begin to be recognized in these shares.”

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net

[QualityStocks]

Pressure Biosciences Inc. (PBIO.OB) Offers Pressure Cycling Technology for a Number of Sample Preparations

Biological samples comprised of difficult to solubilize structural elements can only be solibulized with fully dissolved analytes, destroying the homogeneity of the samples. These processes are also difficult and time consuming. A new approach however has been developed by Pressure Biosciences Inc. that utilizes alternating levels of Hydrostatic pressure resulting in better preserved Bio samples.

The process they have developed is a considerable advancement over other methods of sample preparation. Barocycler NEP3229 was developed to generate alternating levels of hydrostatic pressure. It allows up to 3 samples to be processed simultaneously in minutes. Extraction parameters can be optimized to the specific sample types and can be conducted in a variety of organic solvents.

Some common challenges of sample preparation include: Rigid cell walls, High Protein and Lipid counts, Mineralization, Digestive enzymes, and complex matrices. All of these can effectively be prepared by the company’s device.

In order for Molecular analysis to be done, the samples must be carefully prepared. The system created by Pressure Biosciences is a great advancement in the initial sample preparation for genomics, proteomics, and purification of biomolecules from cells and tissues. The technology also offers many advantages including: safety, reproducibility, convenience, and above all precise control over the process. New capabilities and potential sample preparation prospects created by the technology give way to new innovative opportunities in drug discovery, diagnostics, and biotechnology.

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net

[QualityStocks]

Pressure BioSciences, Inc. (PBIO) to be a Featured Company at the 2008 RedChip Conference

RedChip announced today that Pressure BioSciences, along with more than thirty other companies, will be presenting at this year’s RedChip Small-Cap Investor Conference at the Four Seasons Resort in Scottsdale, Arizona on Feb. 7, 2008 from 8 a.m. to 5 p.m.

The RedChip conference will host expo-style exhibitions, networking events, and financial presentations by small-cap companies representing a range of varying sectors. The conference is completely free for pre-qualified investors, but preregistration is required. Those who are pre-qualified will have the opportunity to attend a free cocktail reception and dinner the day before from 6 p.m. to 8:30 p.m.

The following list of companies are scheduled to present: Pressure BioSciences Inc. (Nasdaq:PBIO), GeoPharma Inc. (Nasdaq:GORX), Worldwide Manufacturing USA Inc. (OTCBB:WWMU), Alternative Construction Technologies Inc. (OTCBB:ACCY), Carbon Sciences Inc. (OTCBB:CABN), Duska Therapeutics Inc. (OTCBB:DSKA), Newtek Business Services Inc. (Nasdaq:NEWT), QPC Lasers Inc. (OTCBB:QPCI), Sharps Compliance Corp. (OTCBB:SCOM), ZAGG Inc. (OTCBB:ZAGG), BioSolar Inc. (OTCBB:BSRC) and more.

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net

[QualityStocks]

Pressure Biosciences Inc.’s (PBIO.OB) Technology Noted in Discovery of Potential Biomarkers in Certain Types of Cancers

Scientists at New York University stated that the (ProtoSolve-LRS) was largely responsible for the identification of Biomarkers in Breast and Colon tissue. This machine is the company’s award winning patented technology that uses detergent free extraction of proteins from lipids and other tissues. The research’s results were shown over 2 days at the LC-MS Course symposium at Robison College in Cambridge England.

The company believes that use of its revolutionary technology allows for a better understanding of many disease states including cancer. This is because of the Homogeneity allowed by the companies Pressure Cycling Technology in sample preparation, and use of the patented ProtoSolve-LRS method of protein extraction. Giving researchers what they need to discover potential Biomarkers in many diseases.

Lead research scientists Dr. Paul Pevsner is quoted saying, “Our studies showed that the combination of cycled high pressure (PCT) with the ProteoSolve-LRS kit, used in conjunction with other instrumentation in our laboratory, allowed us to identify potential biomarkers of breast and colon cancer. This is a significant finding, since these potential biomarkers may prove to be important indicators of disease detection and progression. It is possible that these findings may alter the current paradigm of histopathology tissue diagnosis for tumors. In the future, examination of biopsy tissue may require not only histopathology, but also mass spectrometry for complete diagnosis.”

“The combination of PCT and ProteoSolve-LRS is particularly suited for the study of the small, often nano-quantities of samples that are usually available for proteomic studies. The combination of this method with mass spectrometry instrumentation may become a method of choice for bio-molecular identification, not just in cancer, but in neurological and coronary diseases as well,” he added.

Pressure Bioscience is early stage company that is focused on creating and developing innovative technologies specifically the company’s patented technology Pressure Cycling for sample preparation. Its Barocycler NEP3229 uses this technology to process multiple samples within minutes with the ability to customize depending on the sample type needed. They hold 13 US and 4 foreign patents covering many applications of their technology in the life sciences field.

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net